Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ensysce Biosciences Inc (ENSC)

Ensysce Biosciences Inc (ENSC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,921
  • Shares Outstanding, K 3,632
  • Annual Sales, $ 5,210 K
  • Annual Income, $ -7,990 K
  • EBIT $ -11 M
  • EBITDA $ -10 M
  • 60-Month Beta 1.15
  • Price/Sales 1.11
  • Price/Cash Flow N/A
  • Price/Book 5.39

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4600 +12.33%
on 12/03/25
2.1700 -24.42%
on 11/12/25
-0.4400 (-21.15%)
since 11/05/25
3-Month
1.4600 +12.33%
on 12/03/25
2.7500 -40.36%
on 10/16/25
-0.4950 (-23.19%)
since 09/05/25
52-Week
1.4600 +12.33%
on 12/03/25
10.9600 -85.04%
on 12/24/24
-5.6035 (-77.36%)
since 12/05/24

Most Recent Stories

More News
Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

SAN DIEGO, CA / ACCESS Newswire / April 24, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief...

ENSC : 1.6400 (+0.61%)
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

SAN DIEGO, CALIFORNIA / ACCESS Newswire / April 23, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain...

ENSC : 1.6400 (+0.61%)
Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

~ Applies TAAP and MPAR Technology to Produce Novel OUD Treatments ~

ENSC : 1.6400 (+0.61%)
Ensysce Biosciences Stock Rises On Positive Data From Opioid Overdose Protection Study: Retail’s Thrilled

The company stated that a 100 mg dosage of PF614-MPAR delivers oxycodone to treat severe pain and provides overdose protection when a greater-than-prescribed dose is consumed.

VXF : 213.06 (-0.08%)
ENSC : 1.6400 (+0.61%)
Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

~ Additional Evidence of PF614-MPAR Overdose Protection after Completion of Part 1 of Clinical Study ~

ENSC : 1.6400 (+0.61%)
Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SAN DIEGO, CA / ACCESS Newswire / March 31, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe...

ENSC : 1.6400 (+0.61%)
Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

~ Analgesic Experts Consider Pain Indications Versus New Classes of Analgesics ~

ENSC : 1.6400 (+0.61%)
Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

Secures Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

ENSC : 1.6400 (+0.61%)
Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

SAN DIEGO, CA / ACCESS Newswire / March 5, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe...

ENSC : 1.6400 (+0.61%)
Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment

~ Positive Enrollment Progress and Safety Data ~

ENSC : 1.6400 (+0.61%)

Business Summary

Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is involved in developing tamper-proof opioids which prevent both drug abuse and overdoses. Ensysce Biosciences, formerly known as Leisure Acquisition Corp.,...

See More

Key Turning Points

3rd Resistance Point 1.7550
2nd Resistance Point 1.7200
1st Resistance Point 1.6800
Last Price 1.6400
1st Support Level 1.6050
2nd Support Level 1.5700
3rd Support Level 1.5300

See More

52-Week High 10.9600
Fibonacci 61.8% 7.3310
Fibonacci 50% 6.2100
Fibonacci 38.2% 5.0890
Last Price 1.6400
52-Week Low 1.4600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar